英科醫療(300677.SZ)半年度淨利潤升2611.87%至19.21億元 擬10轉5派5元
格隆匯 8 月 27日丨英科醫療(300677.SZ)發佈2020年半年度報告，報告期內公司實現營業收入4,449,795,284.35元，較上年同期增長352.09%；報告期歸屬於上市公司股東淨利潤1,921,301,371.92元，較上年同期增長2,611.87%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤19.22億元，同比增長2627.60%；基本每股收益9.30元；擬每10股派發現金紅利5元(含税)，以資本公積金向全體股東每10股轉增5股。經營活動產生的現金流量淨額25.83億元，同比增長1865.82%。
報告期內，醫療防護類產品的銷售收入4,286,489,176.62元，佔公司營業總收入的96.33%，康復護理類產品銷售收入102,982,836.53元，佔公司營業總收入的2.31%，保健理療類產品銷售收入47,107,573. 95元，佔公司營業總收入的1.06%，檢查耗材類產品銷售收入12,011,359. 02元，佔公司營業總收入的0.27%。報告
報告期內，公司繼續加大手套生產線的建設步伐，安徽英科“年產280億隻(2800萬箱)高端醫用手套項目”中10條丁腈手套生產線建成投產。截至報告期末，手套年化總產能超過220億隻，其中PVC手套產能超140億隻，丁腈手套產能超80億隻。
江蘇英科建設江蘇英科醫療產業基地項目8號車間已建成投入使用，正在進行9號車間的建設，預計2020年底竣工；公司與張店區人民政府簽約在張店區科技工業園投資建設的英科醫療智能醫療器械研發營銷科技園項目正在建設中；公司已開始推進全球化製造進程，通過全資子公司新加坡英科投資為投資路徑在越南設立子公司，實施年產88.2億隻(882萬箱)高端醫用手套及其他醫療耗材項目。
報告期內，受本次新型冠狀病毒的影響，公司判斷未來人們的醫療防護意識會日益增強，未來醫療防護手套市場空間廣闊，同時為緩解快速增長的一次性手套市場需求，完善和豐富公司醫療防護產品品種，促進業務增長，公司在安徽濉蕪產業園區投資22.76億元人民幣實施建設“英科醫療防護用品產業園項目”，並投資2400萬元人民幣建設“年產3億隻口罩及100萬套防護服項目”；在江西彭澤投資30億元人民幣實施建設“年產271.68億隻(2744萬箱)高端醫用手套項目”；在安徽懷寧經開區投資40億元人民幣建設“年產400億隻(4000萬箱)高端醫用手套項目”，並在懷寧經開發區投資10億元人民幣實施熱電聯產項目。目前上述項目正在建設中。
公司輪椅業務集研發、生產、銷售於一身，具備先進的自動化生產設備和智能機器人設備，產品定位中高端市場，並與全球知名康復醫療品牌進行銷售合作，輪椅銷售成為手套業務的有益補充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
